课题基金 / 基金详情

Determining the clinical and environmental impact, burden and cost of Extensively Drug Resistant Enterobacteriaceae in China (DETER-XDRE-CHINA-HUB)

Determining the clinical and environmental impact, burden and cost of Extensively Drug Resistant Enterobacteriaceae in China (DETER-XDRE-CHINA-HUB)
确定中国广泛耐药肠杆菌科细菌的临床和环境影响、负担和成本 (DETER-XDRE-CHINA-HUB)
批准号:
MR/S013768/1
负责人:
Timothy Walsh
金额:
$235.14万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2019
资助国家:
英国
项目状态:
已结题
起止时间:
2019 至 --

项目摘要

项目成果

Timothy Walsh的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Antimicrobial resistance (AMR) is now deemed to be the biggest global threat facing humanity in the 21C. AMR has taken center stage as a global health issue yet most non-specialists are unaware the impact AMR will have on global populations and the potential it has of taking the treatment of infections back to the "dark ages". Therefore, in keeping with the general notion of "One World Health", there clearly needs to a better alignment of thinking and closer co-operation between countries synergizing activities, knowledge and skills to better understand and prevent AMR. Hitherto, most studies around the world studying the impact of AMR have been small, one dimensional and often biased - too focused on AMR bacteria as oppose to studying the whole bacterial population. Two years ago, we published an article with our Chinese colleagues heralding the breech of the last antibiotic, colisitin, that is used to treat the very serious infections caused by already resistant bacteria such as Escherichia coli (commonly known as E. coli). The difference with this new discovery is that the mechanism of colistin resistance (named MCR-1) is mobile i.e. can be readily passed around from one bacteria to another - even between distantly related bacteria. This article reached global acclaim and has been cited over 1000 times reflecting its broad impact. Following on from this discovery and using the same network of Chinese colleagues, hospitals, farming and environmental sectors, we intend to use MCR (MCRPE) and carbapenem-resistant Enterobacteriaceae (E. coli and E. coli-like bacteria)(CRE) as markers to understand how AMR has spread throughout the Chinese human and animal populations (colistin is used in animal feed in China). Firstly, we have a comprehensive sampling platform: work package (WP) 1, normal flora carriage; WP2, primary and secondary care infections; WP3, chicken, duck and pigs including slaughter houses; WP4, flies and wild birds; WP5, Water, soil and waste; WP6, Aquaculture; and WP7, Domestic animals. Pending the type of sample, we will analyze at least 100 samples every 3/6 months to examine seasonal variation and sample from three distinct provinces in China: Shandong, Guangdong and Jiangsu; additionally, we will also chose Qinghai as a control region. Bacteria will be analyzed by basic microbiology techniques and selected to be whole genome sequenced where we can interrogate the bacteria's whole DNA and compare it to other bacteria to see if they have spread from one sector (e.g. flies) to another (e.g. humans). This study will also sequence bacteria in the human gut (called the microbiome) to understand the dynamics of AMR bacterial populations. We will also undertake controlled experiments in chicken farms to monitor the spread on CRE and MRCPE and use mathematical models to understand how AMR spreads in animals. Importantly, the Chinese government has recently (2017) withdrawn the antibiotic colistin so this study is very timely in measuring that effect i.e. will withdrawing colistin impact on MCRPE rates in the environment, human gut levels and MCRPE causing human infections? Unlike previous studies, this study is deliberately holistic in its approach to understand the dynamics and transmission of AMR across a broad range of environmental and human sectors. This study will let us understand the impact of CRE and MCRPE on human populations and the burden and cost to the Chinese health system. It will also help us understand the impact AMR on the chicken, duck and pig trade by using mathematical models. The impact of this study will have immense consequences for the animal, human and economic sectors in China. Our network is well established, high successful and has a proven track record of working together in China and expertise to undertake this exciting and challenging proposal.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1093/cid/ciz1095
发表时间: 2020-10-23
期刊: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子: --
作者: [Andrey DO, Pereira Dantas P, Martins WBS, Marques De Carvalho F, Almeida LGP, Sands K, Portal E, Sauser J, Cayô R, Nicolas MF, Vasconcelos ATR, Medeiros EA, Walsh TR, Gales AC]
通讯作者: Gales AC
Antibiotic resistance, stewardship, and consumption - Authors' reply.
抗生素耐药性、管理和消费——作者的回复。
DOI: 10.1016/s2542-5196(18)30263-8
发表时间: 2019
期刊: The Lancet. Planetary health
影响因子: --
作者: [Collignon P]
通讯作者: Collignon P
DOI: 10.1016/s0140-6736(21)02724-0
发表时间: 2022-02-12
期刊: Lancet (London, England)
影响因子: --
作者: [Antimicrobial Resistance Collaborators]
通讯作者: Antimicrobial Resistance Collaborators
DOI: 10.1038/s41564-020-0775-0
发表时间: 2020-08-17
期刊: NATURE MICROBIOLOGY
影响因子: 28.3
作者: [Hancock, Steven J., Minh-Duy Phan, Schembri, Mark A.]
通讯作者: Schembri, Mark A.
The disulfide bond as a chemical tool in cyclic peptide antibiotics: engineering disulfide polymyxins and murepavadin
  • 批准号:
    MR/Y033809/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $23.35万
  • 财政年份:
    2024
  • 负责人:
    Timothy Walsh
  • 依托单位:
Determining the clinical and environmental impact, burden and cost of Extensively Drug Resistant Enterobacteriaceae in China (DETER-XDRE-CHINA-HUB)
  • 批准号:
    MR/S013768/2
  • 项目类别:
    Research Grant
  • 资助金额:
    $175.04万
  • 财政年份:
    2020
  • 负责人:
    Timothy Walsh
  • 依托单位:
China/UK/Thailand Program on Poultry Biosafety for Salmonella, E. coli and Campylobacter (CUT-SEC)
  • 批准号:
    BB/R012776/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $197.82万
  • 财政年份:
    2018
  • 负责人:
    Timothy Walsh
  • 依托单位:
Determining the clinical and environmental impact, burden and cost of extensively drug resistant Enterobacteriaceae in China (DETER-XDRE-CHINA)
  • 批准号:
    MR/P007295/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $128.01万
  • 财政年份:
    2016
  • 负责人:
    Timothy Walsh
  • 依托单位:
国内基金
海外基金
"胚胎/生殖细胞发育特性激活”促进“神经胶质瘤恶变”的机制及其临床价值研究
  • 批准号:
    82372327
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    马展
  • 依托单位:
OBSL1功能缺失导致多指(趾)畸形的分子机制及其临床诊断价值
  • 批准号:
    82372328
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    项盈
  • 依托单位:
自身免疫性T细胞的抗原决定簇在抗肾小球基底膜病发病中的启动机制
  • 批准号:
    81170645
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2011
  • 负责人:
    崔昭
  • 依托单位:
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data